Prana Biotechnology Limited (ADR)  

(Public, NASDAQ:PRAN)   Watch this stock  
Find more results for PRAN
+0.08 (3.64%)
Real-time:   11:54AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.00 - 2.18
52 week 1.47 - 13.29
Open 2.01
Vol / Avg. 251,220.00/1.26M
Mkt cap 103.65M
P/E     -
Div/yield     -
EPS -0.26
Shares 416.48M
Beta 0.57
Inst. own 0%

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -4181.86% -5161.56%
Operating margin -4141.04% -5171.30%
EBITD margin - -5144.25%
Return on average assets -76.03% -63.79%
Return on average equity -93.66% -79.47%
Employees 9 -
CDP Score - -


Level 2, 369 Royal Parade, Parkville
+61-3-93494906 (Phone)
+61-3-93480377 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Prana Biotechnology Limited (Prana) is development stage company. The Company is engaged in develop therapeutic drugs designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses, initially focusing on Alzheimer�s disease. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company is also focusing on Huntington�s and Parkinson�s diseases. Other potential applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease and age-related cataracts.

Officers and directors

Geoffrey Paul Kempler Executive Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Richard Revelins Chief Financial Officer, Company Secretary
Bio & Compensation  - Reuters
Dianne Angus Chief Operating Officer
Bio & Compensation  - Reuters
Ira Shoulson Director
Bio & Compensation  - Reuters
Lawrence Gozlan Non-Executive Independent Director
Bio & Compensation  - Reuters
Peter Ashley Marks Non-Executive Independent Director
Bio & Compensation  - Reuters
Brian Derek Meltzer Non-Executive Independent Director
Bio & Compensation  - Reuters
George William Mihaly Non-Executive Independent Director
Bio & Compensation  - Reuters